Aurinia Pharmaceuticals Inc (STU:IKAP)
€ 9.252 -0.386 (-4%) Market Cap: 1.32 Bil Enterprise Value: 1.07 Bil PE Ratio: 0 PB Ratio: 3.57 GF Score: 84/100

Aurinia Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) - On-Demand Transcript

Sep 13, 2021 / 07:00PM GMT
Release Date Price: €16.6 (+2.44%)
Wing Cheung Yip
H.C. Wainwright & Co, LLC, Research Division - Research Analyst

Hello, everyone. This is Thomas Yip from H.C. Wainwright. For our next presentation, we have Mr. Peter Greenleaf. He is the CEO and Director of Aurinia Pharmaceuticals, a commercial stage company focused on delivering treatments for serious diseases with a high unmet need. Peter, very happy to have you with us at our conference. Please go ahead.

Peter S. Greenleaf
Aurinia Pharmaceuticals Inc. - President, CEO & Director

Thanks, Tom, and I want to thank everybody at H.C. Wainwright for having us at the conference today. Good afternoon to everyone who is joining us, and I hope the conference is going well for you.

I'm going to spend, I guess, about 20 minutes to walk you through who we are as a company. And if you're aware of who we are, to give you an update on the most recent events and what we've been up to as an organization. But before I do, let me point you to our forward-looking statements. And of course, all of our most recently filed filings with the SEC

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot